LOXL2 and cancer: In order to examine the prognostic value of LOXL2 in pan-cancer patients, we analyzed its expression in relation to patients’ outcomes, concentrating on overall survival (OS), progression-free interval (PFI), disease-free interval (DFI), and disease specific survival (DSS).